Everything about Lars Fruergaard Jørgensen is understated. The chief executive of Danish drugs group Novo Nordisk grew up on a pig farm in Jutland and from an early age was expected to muck out the animals.
While most of his rivals take private jets to their appointments, he waits for commercial connections. Tall, thin and thoughtful, Jørgensen is far from the conventional image of a swashbuckling, dealmaking CEO: he started his career as an economist in the healthcare and planning department.
But in his low-key way, Jørgensen is pioneering a commercial innovation that could have a profound impact not just on healthcare, but on societies, on public finances and on our relationship with food.
您已閱讀4%（700字），剩餘96%（14961字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。